Reduced amplitude of the sural nerve sensory action potential in PARK2 patients.
The authors performed nerve conduction studies in nine PARK2 and eight idiopathic Parkinson disease patients and found a significant reduction of sural sensory nerve action potential (SNAP) amplitude in eight PARK2 patients who mostly remained asymptomatic. These data suggest that sensory axonal neuropathy may be a common clinical feature of PARK2 and a reduced amplitude of sural SNAP could be a diagnostic indicator of PARK2.
Ohsawa
Y
Y
Division of Neurology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki-City, Okayama 701-0192, Japan.
Kurokawa
K
K
Sonoo
M
M
Yamada
H
H
Hemmi
S
S
Iwatsuki
K
K
Hagiwara
H
H
Murakami
T
T
Shirabe
T
T
Shimizu
T
T
Sunada
Y
Y
D000200:Action Potentials / Q000502:physiology; D000328:Adult; D004568:Electrodiagnosis; D005260:Female; D005727:Ganglia, Spinal / Q000378:metabolism; D005728:Ganglia, Sympathetic / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000502:physiology; D010292:Paresthesia / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D020734:Parkinsonian Disorders / Q000150:complications* / Q000175:diagnosis* / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis* / Q000209:etiology* / Q000503:physiopathology; D012333:RNA, Messenger / Q000378:metabolism; D012678:Sensation Disorders / Q000175:diagnosis* / Q000209:etiology* / Q000503:physiopathology; D013497:Sural Nerve / Q000503:physiopathology*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics
D012333:RNA, Messenger; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein